Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
18
2
3
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
27.8%
5 terminated/withdrawn out of 18 trials
64.3%
-22.2% vs industry average
6%
1 trials in Phase 3/4
56%
5 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
Role: lead
Phase 1b Study of DCR-AUD in Healthy Volunteers
Role: lead
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
Role: lead
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
Role: lead
A Study of DCR-STAT3 in Adults With Solid Tumors
Role: lead
Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
Role: lead
Long Term Extension Study in Patients With Primary Hyperoxaluria
Role: lead
A Study of Belcesiran in Patients With AATLD
Role: lead
Study of DCR-AUD in Healthy Volunteers
Role: lead
Natural History of Patients With PH3 and a History of Stone Events
Role: lead
Study of DCR-A1AT in Healthy Adult Volunteers
Role: lead
Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients
Role: lead
An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
Role: lead
Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
Role: lead
Study of Safety and Tolerability of DCR HBVS
Role: lead
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
Role: lead
Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma
Role: lead
A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)
Role: lead
All 18 trials loaded